Header cover image

U.K. (FTSE) Pharma Industry Analysis

UpdatedJun 08, 2023
DataAggregated Company Financials
Companies26
  • 7D1.4%
  • 3M5.6%
  • 1Y-4.0%
  • YTD0.4%

Over the last 7 days, the Pharma industry has risen 2.7%, driven by gains from AstraZeneca of 2.9%. Despite this gain, the industry's performance has been flat over the past year. Looking forward, earnings are forecast to grow by 19% annually.

Industry Valuation and Performance

Has the U.K. Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Thu, 08 Jun 2023UKĀ£251.2bUKĀ£68.6bUKĀ£8.0b55.5x31.5x3.7x
Sat, 06 May 2023UKĀ£258.0bUKĀ£68.0bUKĀ£7.9b57.3x32.6x3.8x
Mon, 03 Apr 2023UKĀ£243.3bUKĀ£69.5bUKĀ£6.9b51.9x35.3x3.5x
Wed, 01 Mar 2023UKĀ£238.7bUKĀ£70.3bUKĀ£7.0b53x33.9x3.4x
Fri, 27 Jan 2023UKĀ£235.3bUKĀ£79.1bUKĀ£6.3b38.3x37.4x3x
Sun, 25 Dec 2022UKĀ£245.2bUKĀ£80.2bUKĀ£6.3b37.7x38.7x3.1x
Tue, 22 Nov 2022UKĀ£239.4bUKĀ£81.1bUKĀ£6.4b26.6x37.5x3x
Thu, 20 Oct 2022UKĀ£218.1bUKĀ£80.9bUKĀ£3.7b20.4x59.6x2.7x
Sat, 17 Sep 2022UKĀ£221.6bUKĀ£80.2bUKĀ£3.7b15.1x60.2x2.8x
Mon, 15 Aug 2022UKĀ£237.6bUKĀ£77.8bUKĀ£3.8b14.9x63.2x3.1x
Wed, 13 Jul 2022UKĀ£274.5bUKĀ£75.5bUKĀ£4.5b16.1x60.4x3.6x
Fri, 10 Jun 2022UKĀ£254.9bUKĀ£73.7bUKĀ£4.6b16.4x55.7x3.5x
Sun, 08 May 2022UKĀ£262.3bUKĀ£74.1bUKĀ£4.6b17.2x57.4x3.5x
Tue, 05 Apr 2022UKĀ£256.6bUKĀ£66.5bUKĀ£4.8b19.8x53.4x3.9x
Thu, 03 Mar 2022UKĀ£239.6bUKĀ£66.1bUKĀ£4.8b31.2x50.4x3.6x
Sat, 29 Jan 2022UKĀ£235.8bUKĀ£61.5bUKĀ£5.6b31.9x41.8x3.8x
Mon, 27 Dec 2021UKĀ£233.6bUKĀ£61.6bUKĀ£5.6b32.1x41.4x3.8x
Wed, 24 Nov 2021UKĀ£227.2bUKĀ£61.6bUKĀ£5.7b31x40.2x3.7x
Fri, 22 Oct 2021UKĀ£227.0bUKĀ£58.1bUKĀ£7.5b27.2x30.4x3.9x
Sun, 19 Sep 2021UKĀ£215.7bUKĀ£58.2bUKĀ£7.5b29.4x28.7x3.7x
Tue, 17 Aug 2021UKĀ£230.5bUKĀ£58.1bUKĀ£7.5b26.9x30.7x4x
Tue, 01 Jun 2021UKĀ£190.4bUKĀ£56.2bUKĀ£8.5b26.8x22.4x3.4x
Fri, 05 Mar 2021UKĀ£166.1bUKĀ£57.2bUKĀ£8.3b33.9x20.1x2.9x
Mon, 07 Dec 2020UKĀ£186.6bUKĀ£57.9bUKĀ£8.4b41.7x22.1x3.2x
Thu, 10 Sep 2020UKĀ£198.1bUKĀ£59.5bUKĀ£8.5b44.1x23.2x3.3x
Price to Earnings Ratio

24.1x


Total Market Cap: UKĀ£205.7bTotal Earnings: UKĀ£8.5bTotal Revenue: UKĀ£59.5bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Pharma Industry Price to Earnings3Y Average 37.8x202120222023
Current Industry PE
  • Investors are pessimistic on the British Pharmaceuticals industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 31.7x which is lower than its 3-year average PE of 37.8x.
  • The industry is trading close to its 3-year average PS ratio of 3.5x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have declined 2.3% per year over the last three years.
  • Meanwhile revenues for these companies have grown 4.9% per year.
  • This means that although more sales are being generated, either the cost of doing business or the level of investment back into businesses has increased, which has decreased profits.

Industry Comparison

How does U.K. Pharma compare with similar industries?

GB Market2.27%
Healthcare1.22%
Pharma1.39%
Pharma1.39%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AZN AstraZenecaUKĀ£117.540.8%
+UKĀ£1.5b
14.0%PE48.2x
GSK GSKUKĀ£13.762.2%
+UKĀ£1.2b
-37.1%PE12.5x
INDV IndiviorUKĀ£17.1617.9%
+UKĀ£359.9m
8.5%PS3.1x
DPH Dechra PharmaceuticalsUKĀ£36.268.6%
+UKĀ£325.7m
3.2%PE103x
HCM HUTCHMED (China)UKĀ£2.003.5%
+UKĀ£57.6m
8.7%PS4.9x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

GSK

UKĀ£13.76

GSK

7D

2.2%

1Y

-37.1%

CEL

UKĀ£1.58

Celadon Pharmaceuticals

7D

-6.0%

1Y

51.4%

AZN

UKĀ£117.54

AstraZeneca

7D

0.8%

1Y

14.0%

DPH

UKĀ£36.26

Dechra Pharmaceuticals

7D

8.6%

1Y

3.2%

HCM

UKĀ£2.00

HUTCHMED (China)

7D

3.5%

1Y

8.7%

POLB

UKĀ£0.084

Poolbeg Pharma

7D

7.7%

1Y

50.0%

APH

UKĀ£0.60

Alliance Pharma

7D

-2.6%

1Y

-47.9%

INDV

UKĀ£17.16

Indivior

7D

17.9%

1Y

8.5%

NFX

UKĀ£0.0024

Nuformix

7D

-11.3%

1Y

-41.3%

SAR

UKĀ£1.30

Sareum Holdings

7D

13.0%

1Y

-41.0%

KNB

UKĀ£0.02

Kanabo Group

7D

-24.0%

1Y

-50.6%

EAH

UKĀ£1.04

ECO Animal Health Group

7D

-7.6%

1Y

-13.3%

APOL

UKĀ£0.0016

Apollon Formularies

7D

-8.6%

1Y

-91.1%